Information Mediary Corp (IMC) and Adherence have
collaborated to introduce a digitized Morisky Medication Adherence
Scale (MMAS), revolutionizing medication adherence
management.
NEW
YORK, May 6, 2024 /PRNewswire/ -- Information
Mediary Corp (IMC) and Adherence have collaborated to introduce a
digitized Morisky Medication Adherence Scale (MMAS),
revolutionizing medication adherence management. This innovative
solution signifies a significant advancement in precision and
efficiency in patient care.
The Morisky scale plays a crucial role in ensuring patients
adhere to their prescribed medications, directly impacting
treatment outcomes by preventing disease progression, reducing
complications, and enhancing overall health outcomes.
Recognized as the gold standard for assessing medication
adherence, the MMAS-4 and MMAS-8 have been referenced in over
31,298 academic journals.
This new partnership combines IMC's cutting-edge dose analytics
with Adherence's expertise to create a solution that integrates
patient-reported MMAS data with objective adherence information.
Through this collaboration, IMC will seamlessly integrate MMAS with
the CertiScan Adherence Insight Platform, eCAP, and Med-ic,
providing partners with a comprehensive suite of tools for advanced
adherence monitoring and improved patient outcomes.
A key focus of this partnership is the development of APIs for
third-party platform integration. This initiative will enable
industry partners to leverage the benefits of this innovative
solution across various healthcare settings.
Dean Brotzel, CTO of IMC,
emphasized, "The digital MMAS integration marks a significant
milestone in medication adherence monitoring. By leveraging
combined data sources, we are transforming the approach healthcare
providers and patients take towards medication adherence."
For media inquiries or more information on the groundbreaking
collaboration between IMC and Adherence, please contact
dbrotzel@informationmediary.com or Philip.morisky@adherence.cc
About Information Mediary Corp (IMC): IMC is at the
forefront of developing smart packaging solutions that integrate
cutting-edge technology to enhance patient safety, medication
adherence, and healthcare outcomes.
IMC's Med-ic® is the only Smart Dose blister ever submitted with
a FDA priority review resulting in a blockbuster drug approval.
Over a million smart Med-ic blisters have been used over the past
few years to gather valuable adherence data from over 20 million
doses in pivotal clinical trials with customers such as AbbVie and
Merck. InformationMediary.com
About Adherence: The MMAS (Morisky Medication
Adherence Scale), developed by Dr. Donald
Morisky and several co-authors, is a 4 and 8 item
self-report questionnaire that evaluates medication adherence by
probing behaviors like medication forgetting or discontinuation.
The MMAS is widely applied in healthcare research and clinical
practice, aiding in the identification of patients at risk of
non-adherence and guiding the customization of adherence
interventions.
Adherence serves as the catalyst with pharmaceutical firms,
telehealth initiatives, and IT platforms seamlessly integrating
MMAS into their systems and procedures. MMAS is intricately woven
into defined protocols for standards of care, endpoints and
outcome measures in clinical trials, medication therapy
management, and patient intake processes. adherence.cc
Press contact:
Joanne Watters
6137458400
https://informationmediary.com/
View original content to download
multimedia:https://www.prnewswire.com/news-releases/information-mediary-corp-and-adherence-partner-to-launch-revolutionary-digital-mmas-integration-for-medication-adherence-302137487.html
SOURCE Information Mediary Corp.